Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial

被引:50
作者
Xiao-feng Zhai [1 ]
Zhe Chen [1 ]
Bai Li [1 ]
Feng Shen [2 ]
Jia Fan [3 ]
Wei-ping Zhou [2 ]
Yun-ke Yang [4 ]
Jing Xu [5 ]
Xiao Qin [5 ]
Le-qun Li [6 ]
Chang-quan Ling [1 ]
机构
[1] Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University
[2] Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
[3] Liver Cancer Institute, Fudan University
[4] Department of Traditional Chinese Medicine, Zhongshan Hospital, Fudan University
[5] Department of Hepatic Surgery, the First Affiliated Hospital of Guangxi Medical University
[6] Department of Hepatobiliary Surgery, Tumor Hospital of Guangxi Medical University
关键词
hepatocellular carcinoma; recurrence; traditional Chinese medicine; transarterial chemoembolization; randomized controlled trial;
D O I
暂无
中图分类号
R735.7 [肝肿瘤]; R273 [中医肿瘤科];
学科分类号
100214 ; 1005 ;
摘要
BACKGROUND: Disease recurrence is a main challenge in treatment of hepatocellular carcinoma (HCC). There is no generally accepted method for preventing recurrence of HCC after resection. OBJECTIVE: To compare the efficacy of a traditional herbal medicine (THM) regimen and transarterial chemoembolization (TACE) in preventing recurrence in post-resection patients with small HCC. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a multicenter, open-label, randomized, controlled study, which was undertaken in five centers of China. A total of 379 patients who met the eligibility criteria and underwent randomization were enrolled in this trial. One hundred and eighty-eight patients were assigned to the THM group and received Cinobufacini injection and Jiedu Granule, and the other 191 patients were assigned to the TACE group and received one single course of TACE. MAIN OUTCOME MEASURES: Primary outcome measures were the annual recurrence rate and the time to recurrence. Incidence of adverse events was regarded as the secondary outcome measure. RESULTS: Among the 364 patients who were included in the intention-to-treat analysis, 67 patients of the THM group and 87 of the TACE group had recurrence, with a hazard ratio of 0.695 (P = 0.048). Median recurrence-free survival of the patients in the THM and TACE groups was 46.89 and 34.49 months, respectively. Recurrence rates at 1, 2 and 3 years were 17.7%, 33.0% and 43.5% for the THM group, and 28.8%, 42.5% and 54.0% for the TACE group, respectively (P = 0.026). Multivariate analysis indicated that the THM regimen had a big advantage for prolonging the recurrence-free survival. Adverse events were mild and abnormality of laboratory indices of the two groups were similar. CONCLUSION: In comparison with TACE therapy, the THM regimen was associated with diminished risk of recurrence of small-sized HCC after resection, with comparable adverse events. TRIAL REGISTRTION IDENTIFIER: This trial was registered in the Chinese Clinical Trial Registry with the identifier ChiCTR-TRC-07000033.
引用
收藏
页码:90 / 100
页数:11
相关论文
共 15 条
[1]   经肝动脉化疗栓塞对肝癌术后复发及预后的临床研究 [J].
韦忠恒 ;
浦涧 ;
马燕飞 ;
汪建初 ;
卢冠铭 ;
韦邦宁 .
右江医学, 2011, 39 (04) :403-405+545
[2]   蟾毒灵抗小鼠原位移植性肝癌整体药效学研究 [J].
韩克起 ;
顾伟 ;
苏永华 ;
黄雪强 ;
王喜 ;
凌昌全 .
中华实验外科杂志, 2004, (12) :29-31+185
[3]   肿瘤治疗存在的问题及中西医结合的研究重点 [J].
凌昌全 .
中西医结合学报, 2003, (03) :168-170
[4]   三种蟾毒单体对SMMC-7721和BEL-7402人肝癌细胞生长的抑制作用 [J].
苏永华 ;
尹西才 ;
谢觉民 ;
高波 ;
凌昌全 .
第二军医大学学报, 2003, (04) :393-395
[5]  
Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells[J] . Fanghua Qi,Anyuan Li,Lin Zhao,Huanli Xu,Yoshinori Inagaki,Dongliang Wang,Xiaoyan Cui,Bo Gao,Norihiro Kokudo,Munehiro Nakata,Wei Tang.Journal of Ethnopharmacology . 2010 (3)
[6]  
Novel advancements in the management of hepatocellular carcinoma in 2008[J] . Josep M. Llovet,Jordi Bruix.Journal of Hepatology . 2008
[7]  
A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular Carcinoma[J] . Chung Mau Lo,Chi Leung Liu,See Ching Chan,Chi Ming Lam,Ronnie T. P. Poon,Irene O. L. Ng,Sheung Tat Fan,John Wong.Annals of Surgery . 2007 (6)
[8]  
The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care[J] . Digant Gupta,Christopher G. Lis,Timothy C. Birdsall,James F. Grutsch.Supportive Care in Cancer . 2005 (11)
[9]  
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J] . Josep M. Llovet,Jordi Bruix.Hepatology . 2003 (2)
[10]  
Liver Resection for Hepatocellular Carcinoma on Cirrhosis: Univariate and Multivariate Analysis of Risk Factors for Intrahepatic Recurrence[J] . Giorgio Ercolani,Gian Luca Grazi,Matteo Ravaioli,Massimo Del Gaudio,Andrea Gardini,Matteo Cescon,Giovanni Varotti,Francesco Cetta,Antonino Cavallari.Annals of Surgery . 2003 (4)